KRAS and cancer: While our data further support the concept that KRAS mutant cells show increased sensitivity towards perturbations of DNA replication, it became clear that pharmacological inhibition of DNA replication initiation, e.g. by inhibition of CDC7 in cells harboring a conditionally expressed oncogene, does not suffice for induction of cell death in KRAS mutant cancer cells.